Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Cash from Financing Activities (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Cash from Financing Activities for 4 consecutive years, with $12.7 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 9.23% to $12.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $88.3 million through Dec 2025, up 202.81% year-over-year, with the annual reading at $88.3 million for FY2025, 202.81% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was $12.7 million at Orchestra BioMed Holdings, down from $76.4 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $86.1 million in Q2 2022, with the low at -$10.7 million in Q4 2023.
  • Average Cash from Financing Activities over 4 years is $16.7 million, with a median of $128500.0 recorded in 2023.
  • The sharpest move saw Cash from Financing Activities skyrocketed 375775.0% in 2024, then crashed 1744.44% in 2025.
  • Over 4 years, Cash from Financing Activities stood at -$5.1 million in 2022, then crashed by 110.14% to -$10.7 million in 2023, then soared by 230.39% to $13.9 million in 2024, then dropped by 9.23% to $12.7 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $12.7 million, $76.4 million, and -$428000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.